To Assess the Prevalence, Management Practices, and Clinical Outcomes Associated With Hyperglycemia Among Hospitalized Patients, With a Particular Focus on the Interplay Between Metabolic Biomarkers, Nutritional Status, and Body Composition (CLIOHA)

May 29, 2026 updated by: Surender ., Medanta, The Medicity, India
This was a prospective, observational cross-sectional study conducted at a tertiary care private hospital in India. The study was designed to comprehensively evaluate the prevalence, management strategies, and clinical outcomes of in-hospital hyperglycemia among adult inpatients. The study also explored the associations of metabolic biomarkers-fetuin-A and fibroblast growth factor-21 (FGF-21) as well as sarcopenic obesity and nutritional factors with clinical outcomes, including length of hospital stay (LOS), complications, and mortality. Institutional Ethics Committee approval was obtained prior to study initiation, and written informed consent was secured from all participants

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

362

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • India
    • Haryana
      • Gurgaon, Haryana, India, 122001
        • Division Of Endocrinology & Diabetes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Newly diagnosed type 2 diabetes mellitus (T2DM) or those presenting with hyperglycemia

Description

Inclusion Criteria:

  • Adult patients aged ≥18 years.
  • Patients with known or newly diagnosed type 2 diabetes mellitus (T2DM) or those presenting with hyperglycemia (random blood glucose ≥140 mg/dL) during hospitalization.
  • Both medical and surgical inpatients admitted for ≥24 hours

Exclusion Criteria:

  • Pregnant or lactating women.
  • Patients with type 1 diabetes mellitus or other specific types of diabetes (e.g., pancreatogenic, drug-induced).
  • Patients with chronic liver disease unrelated to diabetes or hepatic dysfunction secondary to viral hepatitis, autoimmune hepatitis, or alcohol abuse.
  • Critically ill patients requiring palliative care or those with advanced malignancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To determine the prevalence of hyperglycemia
Time Frame: 10 Days
To determine the prevalence of hyperglycemia and pre-existing or newly diagnosed type 2 diabetes mellitus (T2DM) among hospitalized patients
10 Days
Assess clinical outcomes associated with hyperglycemia
Time Frame: 10 Days
To assess clinical outcomes associated with hyperglycemia, including in-hospital complications, mortality, need for critical care support, and length of hospital stay (LOS)
10 Days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of sarcopenic obesity
Time Frame: 10 Days
To assess the prevalence of sarcopenic obesity among diabetic and hyperglycemic patients, and to determine its association with metabolic dysfunction and adverse outcomes
10 Days
Analyze serum biomarker level fetuin-A
Time Frame: 10 Days
To analyze serum biomarker level fetuin-A and correlate them with severity of metabolic dysregulation .Serum fetuin-A levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits
10 Days
Analyze serum biomarker level FGF-21
Time Frame: 10 Days
To analyze serum biomarker levels FGF-21 and correlate them with severity of metabolic dysregulation.Serum FGF-21 levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits
10 Days
Analyze serum biomarker level FGF-21
Time Frame: 10 Days
To analyze serum biomarker levels FGF-21 and correlate them with liver fibrosis indices.Serum FGF-21 levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits
10 Days
Analyze serum biomarker level fetuin-A
Time Frame: 10 Days
To analyze serum biomarker level fetuin-A and correlate them with liver fibrosis indices .Serum fetuin-A levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits
10 Days
To assess Impact of diet
Time Frame: 10 Days
To assess the impact of adequacy of dietary on glycemic control and recovery, will measure the Sugar level at Before Breakfast,Before Lunch,Before Dinner
10 Days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medanta, The Medicity, India

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2023

Primary Completion (Actual)

February 1, 2026

Study Completion (Actual)

March 1, 2026

Study Registration Dates

First Submitted

May 14, 2026

First Submitted That Met QC Criteria

May 29, 2026

First Posted (Actual)

June 4, 2026

Study Record Updates

Last Update Posted (Actual)

June 4, 2026

Last Update Submitted That Met QC Criteria

May 29, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1521/2023

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabete Mellitus

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe